Viral RNA silencing suppressors (RSS): Novel strategy of viruses to ablate the host RNA interference (RNAi) defense system

Virus Research

Volumn 155, Issue 1, 2011, Pages 1-9

  Bivalkar Mehla, Shalmali ^a   Vakharia, Janaki ^a   Mehla, Rajeev ^a   Abreha, Measho ^a   Kanwar, Jagat Rakesh ^b   Tikoo, Akshay ^c   Chauhan, Ashok ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DEAKIN UNIVERSITY   (Australia)

^c MEDICAL UNIVERSITY OF THE AMERICAS   (Saint Kitts and Nevis)

Author keywords

Argonaute; Dicer; Ds RNA binding protein; GW WG motif; HIV 1 Tat; Influenza A virus NS1; MiRNA; RISC

Indexed keywords

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 1; PROTEIN E3L; PROTEIN VP35; TAS PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ADENOVIRUS; EBOLA VIRUS; HOST; INFLUENZA VIRUS A; LA CROSSE VIRUS; MEDICAL RESEARCH; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; REVIEW; RNA BINDING; RNA INTERFERENCE; RNA PROCESSING; RNA SILENCING SUPPRESSOR; SPUMA VIRUS; VACCINIA VIRUS; VIRUS ENVELOPE;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; HOST-PATHOGEN INTERACTIONS; PLANTS; RNA INTERFERENCE; RNA, UNTRANSLATED; RNA, VIRAL; VIRAL PROTEINS; VIRULENCE; VIRULENCE FACTORS; VIRUSES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA A VIRUS; INVERTEBRATA; MAMMALIA;

EID: 78650575533     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.10.003     Document Type: Review

References (95)

1. Ahluwalia J.K., Khan S.Z., Soni K., Rawat P., Gupta A., Hariharan M., Scaria V., Lalwani M., Pillai B., Mitra D., Brahmachari S.K. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 2008, 5:117.
2. Alvarado V., Scholthof H.B. Plant responses against invasive nucleic acids: RNA silencing and its suppression by plant viral pathogens. Semin. Cell Dev. Biol. 2009, 20(9):1032-1040.
3. Andersson M.G., Haasnoot P.C., Xu N., Berenjian S., Berkhout B., Akusjärvi G. Suppression of RNA interference by adenovirus virus-associated RNA. J. Virol. 2005, 79(15):9556-9565.
4. Azevedo J., Garcia D., Pontier D., Ohnesorge S., Yu A., Garcia S., Braun L., Bergdoll M., Hakimi M.A., Lagrange T., Voinnet O. Argonaute quenching and global changes in Dicer homeostasis caused by a pathogen-encoded GW repeat protein. Genes Dev. 2010, 24(9):904-915.
5. Bannert H., Muranyi W., Ogryzko V.V., Nakatani Y., Flügel R.M. Co-activators p300 and PCAF physically and functionally interact with the foamy viral trans-activator. BMC Mol. Biol. 2004, 5:16.
6. Barba G., Harper F., Harada T., Kohara M., Goulinet S., Matsuura Y., Eder G., Schaff Z., Chapman M., Miyamura T., Brechot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1200-1205.
7. Barton C.H., Biggs T.E., Mee T.R., Mann D.A. The human immunodeficiency virus type 1 regulatory protein Tat inhibits interferon-induced iNos activity in a murine macrophage cell line. J. Gen. Virol. 1996, 77:1643-1647.
8. Bennasser Y., Jeang K.T. HIV-1 Tat interaction with Dicer: requirement for RNA. Retrovirology 2006, 3:95.
9. Bennasser Y., Yeung M.L., Jeang K.T. HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein TRBP. J. Biol. Chem. 2006, 281:27674-27678.
10. Bergmann M., Garci{dotless}óa-Sastre A., Carnero E., Pehamberger H., Wolff K., Palese P., Muster T. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 2000, 74:6203-6206.
11. Björndal A.S., Szekely L., Elgh F. Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiol. 2003, 3:6.
12. Blakqori G., Delhaye S., Habjan M., Blair C.D., Sánchez-Vargas I., Olson K.E., Attarzadeh-Yazdi G., Fragkoudis R., Kohl A., Kalinke U., Weiss S., Michiels T., Staeheli P., Weber F. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J. Virol. 2007, 81(10):4991-4999.
13. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., Häussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003, 17(3):488-490.
14. Brask J., Chauhan A., Hill R.H., Ljunggren H.G., Kristensson K. Effects on synaptic activity in cultured hippocampal neurons by influenza A viral proteins. Neurovirology 2005, 11(4):395-402.
15. Brigneti G., Voinnet O., Li W.X., Ji L.H., Ding S.W., Baulcombe D.C. Viral pathogenicity determinants are suppressors of transgene silencing in Nicotiana benthamiana. EMBO J. 1998, 17:6739-6746.
16. Bucher E., Hemmes H., de Haan P., Goldbach R., Prins M. The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. J. Gen. Virol. 2004, 85:983-991.
17. Cabradilla C.D., Holloway B.P., Obijeski J.F. Molecular cloning and sequencing of the La Crosse virus S RNA. Virology 1983, 128:463-468.
18. Campbell G.R., Loret E.P. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?. Retrovirology 2009, 6:50.
19. Cardenas W.B., Loo Y.M., Gale M., Hartman A.L., Kimberlin C.R., Martínez-Sobrido L., Saphire E.O., Basler C.F. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
20. Chang H.W., Jacobs B.L. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 1993, 194:537-547.
21. Chang H.W., Watswon J.C., Jacobs B.L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4825-4829.
22. Chauhan A., Hahn S., Gartner S., Pardo C.A., Netesan S.K., McArthur J., Nath A. Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins. FASEB J. 2007, 21(3):777-789.
23. Chauhan A., Tikoo A., Kapur A.K., Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control Release 2007, 117(2). 14-8-162.
24. Chauhan A., Turchan J., Pocernich C., Bruce-Keller A., Roth S., Butterfield D.A., Major E.O., Nath A. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 2003, 278(15):13512-13519.
25. Chen Z., Krug R.M. Selective nuclear export of viral mRNAs in influenza-virus infected cells. Trends Microbiol. 2000, 8:376-383. Book review.
26. Cheng S.M., Li J.C., Lin S.S., Lee D.C., Liu L., Chen Z., Lau A.S. HIV-1 transactivator protein induction of suppressor of cytokine signaling-2 contributes to dysregulation of IFN-gamma signaling. Blood 2009, 113(21):5192-5201.
27. Corbeau P. Interfering RNA and HIV: reciprocal interferences. PLoS Pathog. 2008, 4(9):1-7.
28. de la Luna S., Fortes P., Beloso A., Ortin J. Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. J. Virol. 1995, 69:2427-2433.
29. de Vries W., Haasnoot J., Fouchier R., de Haan P., Berkhout B. Differential RNA silencing suppression activity of NS1 proteins from different influenza A virus strains. J. Gen. Virol. 2009, 90:1916-1922.
30. Delgadillo M.O., Saóenz P., Salvador B., Garci{dotless}óa J.A., Simoón- Mateo C. Human influenza virus NS1 protein enhances viral pathogenicity and acts as an RNA silencing suppressor in plants. J. Gen. Virol. 2004, 85:993-999.
31. Duvet S., Cocquerel L., Pillez A., Cacan R., Verbert A., Moradpour D., Wychowski C., Dubuisson J. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J. Biol. Chem. 1998, 273(48):32088-32095.
32. Ecker J.R., Davis R.W. Inhibition of gene expression in plant cells by expression of antisense RNA. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:5372-5376.
33. El-Shami M., Pontier D., Lahmy S., Braun L., Picart C., Vega D., Hakimi M.A., Jacobsen S.E., Cooke R., Lagrange T. Reiterated WG/GW motifs form functionally and evolutionarily conserved ARGONAUTE-binding platforms in RNAi-related components. Genes Dev. 2007, 21(20):2539-2544.
34. Endo S., Kubota S., Siomi H., Adachi A., Oroszlan S., Maki M., Hatanaka M. A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization. Virus Genes 1989, 3(2):99-110.
35. Fire A., Albertson D., Harrison S.W., Moerman D.G. Production of antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle. Development 1991, 113:503-514.
36. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8324-8326.
37. Gatignol A., Buckler-White A., Berkhout B., Jeang K.T. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 1991, 251:1597-1600.
38. Giannini C., Bréchot C. Hepatitis C virus biology. Cell Death Differ. 2003, 10:S27-38.
39. Guo Z., Chen L.M., Zeng H., Gomez J.A., Plowden J., Fujita T., Katz J.M., Donis R.O., Sambhara S. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor. RIG-I. Am. J. Respir. Cell Mol. Biol. 2007, 36(3):263-269.
40. Haasnoot J., de Vries W., Geutjes E.J., Prins M., de Haan P., Berkhout B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 2007, 3(6):e86.
41. Hale B.G., Randall R.E., Ortín J., Jackson D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89:2359-2376.
42. Hartman A.L., Towner J.S., Nichol S.T. A C-terminal basic amino acid motif of Zaire Ebola virus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328:177-184.
43. Hatada E., Fukuda R. Binding of influenza A virus NS1 protein to dsRNA in vitro. J. Gen. Virol. 1992, 73:3325-3329.
44. Hatada E., Saito S., Okishio N., Fukuda R. Binding of the influenza virus NS1 protein to model genome RNAs. Virology 1997, 78:1059-1063.
45. Hatada E., Takizawa T., Fukuda R. Specific binding of influenza A virus NS1 protein to the virus minus-sense RNA in vitro. J. Gen. Virol. 1992, 73:17-25.
46. Huang J., Wang F., Argyris E., Chen K., Liang Z., Tian H., Huang W., Squires K., Verlinghieri G., Zhang H. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4(+) T lymphocytes. Nat. Med. 2007, 13:1241-1247.
47. Hutvágner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
48. Ji J., Glaser A., Wernli M., Berke J.M., Moradpour D., Erb P. Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. J. Gen. Virol. 2008, 89:2761-2766.
49. Johnson R.F., Bell P., Harty R.N. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol. J. 2006, 3:31.
50. Johnson R.F., McCarthy S.E., Godlewski P.J., Harty R.N. Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J. Virol. 2006, 80:5135-5144.
51. Karn J. Tackling tat. J. Mol. Biol. 1999, 293:235-254.
52. Kien F., Abraham J.D., Schuster C., Kieny M.P. Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. J. Gen. Virol. 2003, 84:561-566.
53. Kanwar J.R., Mahidhara G., Kanwar R.K. MicroRNA in human cancer and chronic inflammatory diseases. Front. Biosci. 2010, 15(June):1113-1126.
54. Karlowski W.M., Zielezinski A., Carrère J., Pontier D., Lagrange T., Cooke R. Genome-wide computational identification of WG/GW Argonaute-binding proteins in Arabidopsis. Nucleic Acids Res. 2010, 38(13):4231-4245.
55. Kitajewski J., Schneider R.J., Safer B., Shenk T. An adenovirus mutant unable to express VAI RNA displays different growth responses and sensitivity to interferon in various host cell lines. Mol. Cell. Biol. 1986, 6:4493-4498.
56. Kitajewski J., Schneider R.J., Safer B., Munemitsu S.M., Samuel C.E., Thimmappaya B., Shenk T. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 1986, 45(2):195-200.
57. Kok K.H., Jin D.Y. Influenza A virus NS1 protein does not suppress RNA interference in mammalian cells. J. Gen. Virol. 2006, 87:2639-2644.
58. Langland J.O., Jacobs B.L. Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. Virology 2004, 324(2):419-429.
59. Lantermann M., Schwantes A., Sliva K., Sutter G., Schnierle B.S. Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. Virus Res. 2007, 126:1-8.
60. Lecellier C.H., Dunoyer P., Arar K., Lehmann-Che J., Eyquem S., Himber C., Saib A., Voinnet O. A cellular microRNA mediates antiviral defense in human cells. Science 2005, 308:557-560.
61. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
62. Li W.X., Li H., Lu R., Li F., Dus M., Atkinson P., Brydon E.W., Johnson K.L., García-Sastre A., Ball L.A., Palese P., Ding S.W. Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc. Natl. Acad. Sci. USA 2004, 101:1350-1355.
63. Lin J., Cullen B.R. Analysis of the interaction of primate retroviruses with the human RNA interference machinery. J. Virol. 2007, 81(22):12218-12226.
64. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A., Holtzman M.J., Chung R.T. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 2006, 80(18):9226-9235.
65. Linial M.L. Why aren't foamy viruses pathogenic?. Trends Microbiol. 2000, 8:284-289.
66. Liu J., Lynch P.A., Chien C.Y., Montelione G.T., Krug R.M., Berman H.M. Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat. Struct. Biol. 1997, 4:896-899.
67. Liu J., Rivas F.V., Wohlschlegel J., Yates J.R., Parker R., Hannon G.J. A role for the P-body component GW182 in microRNA function. Nat. Cell Biol. 2005, 7:1261-1266.
68. Lu S., Cullen B.R. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J. Virol. 2004, 78:12868-12876.
69. Marq J.B., Hausmann S., Luban J., Kolakofsky D., Garcin D. The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA- and DNA-induced activation of interferon beta. J. Biol. Chem. 2009, 284(38):25471-25478.
70. Mathews M.B., Shenk T. Adenovirus virus-associated RNA and translation control. J. Virol. 1991, 65:5657-5662.
71. Matskevich A.A., Moelling K. Dicer is involved in protection against influenza A virus infection. J. Gen. Virol. 2007, 88:2627-2635.
72. McJunkin J.E., de los Reyes E.C., Irazuzta J.E., Caceres M.J., Khan R.R., Minnich L.L., Fu K.D., Lovett G.D., Tsai T., Thompson A. La Crosse encephalitis in children. N. Engl. J. Med. 2001, 344:801-807.
73. McKenna S.A., Kim I., Liu C.W., Puglisi J.D. Uncoupling of RNA binding and PKR kinase activation by viral inhibitor RNAs. J. Mol. Biol. 2006, 358(5):1270-1285.
74. Melen K., Kinnunen L., Fagerlund R., Ikonen N., Twu K.Y., Krug R.M., Julkunen I. Nuclear and nucleolar targeting of influenza A virus NS1 protein: striking differences between different virus subtypes. J. Virol. 2007, 81:5995-6006.
75. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 2009, 50(3):453-460.
76. Newby C.M., Sabin L., Pekosz A. The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells. J. Virol. 2007, 81:9469-9480.
77. Otsuka M., Jing Q., Georgel P., New L., Chen J., Mols J., Kang Y.J., Jiang Z., Du X., Cook R., Das S.C., Pattnaik A.K., Beutler B., Han J. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 2007, 27:123-134.
78. Ouellet D.L., Plante I., Landry P., Barat C., Janelle M.E., Flamand L., Tremblay M.J., Provost P. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res. 2008, 36(7):2353-2365.
79. Qian S., Zhong X., Yu L., Ding B., de Haan P., Boris-Lawrie K. HIV-1 Tat RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(2):605-610.
80. Santolini E., Migliaccio G., La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 1994, 68(6):3631-3641.
81. Sen G.L., Blau H.M. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat. Cell Biol. 2005, 7(6):633-636.
82. Soldan S.S., Plassmeyer M.L., Matukonis M.K., González-Scarano F. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. J. Virol. 2005, 79:234-244.
83. St.Johnston D., Brown N.H., Ga J.G., Jantsch M. A conserved double-stranded RNA-binding domain. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10979-10983.
84. Suzuki R., Matsuura Y., Suzuki T., Ando A., Chiba J., Harada S., Saito I., Miyamura T. Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted. J. Gen. Virol. 1995, 76:53-61.
85. Triboulet R., Mari B., Lin Y.L., Chable-Bessia C., Bennasser Y., Lebrigand K., Cardinaud B., Maurin T., Barbry P., Baillat V., Reynes J., Corbeau P., Jeang K.T., Benkirane M. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007, 315(5818):1579-1582.
86. Wang F.Z., Weber F., Croce C., Liu C.G., Liao X., Pellett P.E. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J. Virol. 2008, 82:9065-9074.
87. Wang W., Riedel K., Lynch P., Chien C.Y., Montelione G.T., Krug R.M. RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 1999, 5:195-205.
88. Wang Y., Kato N., Jazag A., Dharel N., Otsuka M., Taniguchi H., Kawabe T., Omata M. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 2006, 130(3):883-892.
89. Weber F., Wagner V., Kessler N., Haller O. Induction of interferon synthesis by the PKR-inhibitory VA RNAs of adenoviruses. J. Interferon Cytokine Res. 2006, 26(1):1-7.
90. Westerhout E.M., Ooms M., Vink M., Das A.T., Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 2005, 33:796-804.
91. Yasui K., Wakita T., Tsukiyama-Kohara K., Funahashi S.I., Ichikawa M., Kajita T., Moradpour D., Wands J.R., Kohara M. The native form and maturation process of hepatitis C virus core protein. J. Virol. 1998, 72:6048-6055.
92. Yuwen H., Cox J.H., Yewdell J.W., Bennink J.R., Moss B. Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 1993, 195(2):732-744.
93. Zeng Y., Cullen B.R. Sequence requirements for micro RNA processing and function in human cells. RNA 2003, 9:112-123.
94. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9779-9784.
95. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform. 2008, 9:40.